Phase I S tudy o f R ecombinant H uman E ndostatin i n Patients W ith A dvanced S olid T umors
暂无分享,去创建一个
L. Ellis | K. Hess | W. Hong | R. Herbst | C. Charnsangavej | N. Mullani | D. McConkey | J. Abbruzzese | H. Tran | T. Madden | D. Davis | J. Pluda | J. Tseng
[1] F. Khuri,et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] L. Ellis,et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Herbst,et al. Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Peters,et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. D'Amato,et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. , 2001, Cancer research.
[6] A. Camargo,et al. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. , 2001, Cancer research.
[7] D. Narum,et al. Endostatin Binds Tropomyosin , 2001, The Journal of Biological Chemistry.
[8] R. B. Campbell,et al. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy , 2001, Nature Medicine.
[9] C. Logothetis,et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] A. Feldman,et al. Serum endostatin levels are elevated in patients with soft tissue sarcoma , 2001, Cancer.
[11] C. Kuo,et al. The Nc1/Endostatin Domain of Caenorhabditis elegans Type Xviii Collagen Affects Cell Migration and Axon Guidance , 2001, The Journal of cell biology.
[12] A. Feldman,et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] A. Blann,et al. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. , 2000, Journal of the National Cancer Institute.
[14] J W Baish,et al. Fractals and cancer. , 2000, Cancer research.
[15] M. Makuuchi,et al. Serum endostatin levels in patients with hepatocellular carcinoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] I. B. Borel Rinkes,et al. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. , 2000, Cancer research.
[17] E. Eisenhauer. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] E. Ruoslahti,et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.
[19] Thomas Boehm,et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.
[20] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[21] J. Folkman,et al. Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.
[22] L. Ellis,et al. The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.
[23] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[24] J. Folkman,et al. Proceedings: Tumor angiogenesis factor. , 1974, Cancer research.
[25] N. MacDonald,et al. Angiostatin and Endostatin: Endogenous Inhibitors of Tumor Growth , 2004, Cancer and Metastasis Reviews.
[26] A. Fortier,et al. Zinc ligand-disrupted recombinant human Endostatin: Potent inhibition of tumor growth, safety and pharmacokinetic profile , 2004, Angiogenesis.
[27] R Simon,et al. Clinical trial designs for cytostatic agents: are new approaches needed? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] R. Bicknell. Vascular targeting and the inhibition of angiogenesis. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.